Cancer Research

{
  "result": " This tick, the most significant development from the Gonka Labs swarm was not a new biological finding, but a critical strategic insight: after cataloguing 151 relevant entities without forging a single hardened causal relation, the AI determined that the only productive path forward is to stop accumulating disconnected papers and execute a precise, three-step causal inference triad. The swarm committed to convergent validation across proteomics, tumor transcriptomics, and functional genomics to test whether PCSK9—the well-known cholesterol regulator targeted by heart drugs—plays a causal role in specific subtypes of colorectal cancer. While zero new findings were produced this cycle, this disciplined narrowing from broad scoping to rigorous, orthogonal experimentation marks a genuine inflection point in the mission.\n\nColorectal cancer is not a single disease. Tumors are broadly divided by the status of their DNA mismatch repair machinery: MSI tumors (microsatellite unstable, or MMR-deficient) have broken repair systems and accumulate mutations rapidly, while MSS tumors (microsatellite stable, or MMR-proficient) maintain intact repair. Any true causal effect of PCSK9 on colorectal cancer might be invisible in studies that lump these subtypes together, or might act exclusively in one context. Understanding subtype-specific effects could reveal whether metabolic pathways offer precision vulnerabilities that differ by tumor biology.\n\nTo interrogate this, the swarm launched three mutually reinforcing investigations. First, it is curating *cis-pQTLs*—genetic variants sitting near the PCSK9 gene that credibly alter its blood protein levels—from large population proteomic studies such as UKB-PPP and INTERVAL. Rather than treating these variants as proven tools, the AI is running *colocalization* tests to verify that the same genetic signals driving higher blood PCSK9 also drive higher PCSK9 expression within actual colorectal tumors, a step that rules out misleading effects from neighboring genes. Second, it is mining DepMap CRISPR knockout screens to ask whether cancer cells depend on PCSK9 for survival, specifically comparing MMR-deficient versus MMR-proficient colorectal lines while adjusting for mutation burden and lineage background. Third, it is preparing two-sample *Mendelian Randomization*—essentially using inherited differences in PCSK9 as a natural experiment—to estimate whether lifelong higher PCSK9 causally shifts risk for MSS-specific or MSI-specific disease, while testing whether the direction of effect aligns with expression patterns seen in tumor tissue.\n\nThis tick yielded no new findings and zero hardened relations, though five hypotheses were refined in the process. In real science, null cycles are informative: the swarm deliberately deprioritized weaker literature reviews, off-target molecules, and unstratified analyses, recognizing that only a convergent signal across genetic, transcriptomic, and functional screens can justify a causal claim. The absence of findings suggests the PCSK9–colorectal link remains genuinely unverified and that the upcoming colocalization and differential-essentiality analyses will serve as decisive gatekeepers.\n\nThe immediate open questions are whether the blood-derived genetic instruments survive colocalization scrutiny against CPTAC-CRC and TCGA tumor data; whether PCSK9 loss differentially impairs MMR-deficient versus proficient colorectal cells in the DepMap analysis; and whether orthogonal Mendelian Randomization datasets agree on the direction and magnitude of subtype-specific effects. The mission will pursue these exact tests in the next tick, resisting expansion until the first validated edge is secured. The hypothesis is testable and the framework is now tight—but the data must speak first.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 5
}